試す 金 - 無料
"The pharma packaging landscape is evolving rapidly, driven by advancements in technology and changing regulatory landscapes"
Bio Spectrum
|BioSpectrum India Jan 2025
Recently elevated from CEO to Chairman and Managing Director (CMD) of Ecobliss India, AVPS Chakravarthi, has been at the forefront of developing eco-friendly packaging technologies, particularly for the pharma, biotechnology and allied industries, worldwide.
-

Chakravarthi, with over two decades of experience, has turned Ecobliss India into a pioneer in the field of blister packaging, catering to industries such as pharmaceuticals, food, and FMCG. Apart from his corporate endeavours, he serves as a global ambassador for the World Packaging Organization (WPO), promoting best practices in packaging to reduce environmental impact. He has also been recognised with numerous awards for his contributions to the industry, including honours for innovation and leadership in sustainable packaging. In an interview with BioSpectrum, Chakravarthi shares his perspective and insights into the new and emerging trends in pharmaceutical packaging and the future ahead. Edited excerpts:
Could you tell us about your journey from being the CEO and presently to CMD of Ecobliss India?
The transition to CMD is not a significant milestone as it is business as usual. However, personally, it is a moment of pride, reflecting the trust and faith my team and stakeholders have in me. It allows me to focus on strategic growth, mentorship, and steering Ecobliss India toward greater innovation and sustainability. I believe this position enables me to amplify the company’s vision and legacy in the pharmaceutical packaging sector.
In this role, I see myself as more of a mentor and guide. It’s about empowering my team, encouraging fresh ideas, and ensuring that Ecobliss remains a leader in the pharmaceutical packaging industry. Sustainability and innovation are close to my heart, and this position enables me to champion these values more effectively, aligning the company’s goals with global demands for eco-friendly solutions.
What are your immediate priorities and longterm strategies for steering Ecobliss India’s growth, especially in the pharmaceutical packaging domain?
このストーリーは、Bio Spectrum の BioSpectrum India Jan 2025 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、9,500 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Bio Spectrum からのその他のストーリー

Bio Spectrum
WHO certifies Suriname malaria-free
Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).
1 min
August 2025

Bio Spectrum
Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation
Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.
1 min
August 2025
Bio Spectrum
Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab
Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.
1 min
August 2025
Bio Spectrum
Illumina buys SomaLogic for $425 M to accelerate proteomics business
Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.
1 min
August 2025

Bio Spectrum
Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26
Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.
1 min
August 2025
Bio Spectrum
WHO highlights risks associated with use of semaglutide medicines
The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.
1 min
August 2025

Bio Spectrum
Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin
Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.
1 min
August 2025

Bio Spectrum
AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru
AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.
1 min
August 2025

Bio Spectrum
Novo Nordisk launches injectable Semaglutide for weight management in India
Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.
1 min
August 2025

Bio Spectrum
Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?
India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.
12 mins
August 2025
Listen
Translate
Change font size